FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Go back to FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 220.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $220.83 | 52 Week High | $333.65 | |||
| Open | $220.83 | 52 Week Low | $223.02 | |||
| Day High | $220.83 | P/E | 28.28 | |||
| Day Low | $220.83 | EPS | $7.81 | |||
| Volume | 604 | |||||
